Furqan M, et al. - Investigators compared the toxicity and effectiveness of weekly cisplatin-paclitaxel (CP) regimen with high-dose cisplatin (Cis) in locally advanced head and neck squamous cell cancer (LAHNSCC). Cis and CP groups had 114 and 111 subjects, respectively. They noted 88% as the complete response for both Cis and CP groups. They observed no significant differences between Cis and CP groups for overall survival, progression-free survival, locoregional control, and distant control, after adjusting for potential treatment selection bias. Both acute and chronic toxicities were lower in participants in the CP group. In LAHNSCC patients for whom Cis is not appropriate, they suggested weekly CP regimen as an alternative systemic treatment with radiation.